Purpose:

To report visual outcomes after implantation of the only FDA-approved trifocal intraocular lens (IOL), PanOptix (Alcon), after cataract surgery at a single center.

Methods:

Retrospective chart review of 149 patients undergoing cataract surgery with implantation of the PanOptix IOL performed by two surgeons (n=149). Outcomes measured include pre-operative best-corrected visual acuity (BCVA) and post-operative uncorrected visual acuity (UCVA) at distance, intermediate, and near at post-operative day 1 (POD1), week 1 (POW1), month 1 (POM1), and month 3 (POM3). Manifest refractive spherical equivalent (MRSE) will also be measured. Any adverse events will also be documented.

Results:

On POW1, measuring UCDVA, 40.4% saw 20/20 or better, 95.0% saw 20/40 or better, and 100% saw 20/100 or better. For UCNVA, 18.2% saw 20/20 or better, 83.3% saw 20/40 or better, and 100% saw 20/80 or better. On POM1, measuring UCDVA, 38.9% saw 20/20 or better, 96.7% saw 20/40 or better, & 100% saw 20/80 or better. For UCNVA, 22.0% saw 20/20 or better, 89.8% saw 20/40 or better, and 98.3% saw 20/60 or better. On POM3, measuring UCDVA, 30.1% saw 20/20 or better and 100% saw 20/40 or better. For UCNVA, 9.1% saw 20/20 or better, 78.8% saw 20/40 or better, and 97.0% saw 20/70 or better. Average MRSE was -0.073 ± 0.416 D, -0.041 ± 0.405 D, and -0.083 ± 0.407 D for POW1, POM1, and POM3, respectively.

Conclusions:

The diffractive-refractive trifocal lens, TFAT Panoptix lens from Alcon, provides effective distance and near visual acuity for patients.